Figure 2. Increased periostin expression correlates with pancreatic cancer progression and poor patient survival.

(A) Immunohistochemical staining of pancreatic cancer and matched normal tissues with anti-periostin antibody. A total of 100 patient samples were stained and representative patient samples of clinical stages T1, T2, and T3 are shown. (B) Quantitative analysis of periostin staining in 80 normal tissues and 100 cancer samples showed notably higher staining intensity in pancreatic cancer samples compared with matched normal tissues (IOD, integral optical density). (C) Periostin staining intensity according to the clinical stage of pancreatic cancer samples (n = 100). (D) Upregulated periostin expression positively correlated with the clinical stage of pancreatic cancer (n = 16 in the low-expression group, n = 64 in the high-expression group). (E) High intensity of periostin immunostaining was significantly associated with poor survival. Data are shown as means ± SD. ^*P < 0 .05.